Monitor upcoming FDA feedback in Q2 2026 on the LX2006 pivotal trial protocol, which could be a significant catalyst. The strong cash position and advancing clinical pipeline de-risk the near-term outlook.
Price Chart
Executive Summary
Lexeo Therapeutics reported Q4 2025 financials with a narrow loss of $0.27 per share, beating consensus by 15.6%, while maintaining strong operational momentum in its LX2006 and LX2020 gene therapy programs. The company highlighted FDA alignment on pivotal trials, positive clinical data presentations at ACC, and a strengthened leadership team, all supported by a $246.6M cash position extending into 2028. The combination of a small earnings beat and significant positive pipeline developments is bullish.
Key Financial Metrics
Key Facts
- Q4 2025 EPS was $-0.27, beating consensus of $-0.30 by 15.6%
- Cash position increased to $246.6 million, sufficient to fund operations into 2028
- Positive interim clinical data for both LX2006 (Friedreich ataxia) and LX2020 (PKP2-ACM) presented at ACC
- FDA feedback on pivotal trial protocol for LX2006 expected in Q2 2026, with study initiation on track for 1H 2026
- Appointed new Chief Medical Officer, Dr. Narinder Bhalla, from Bristol Myers Squibb and AstraZeneca
Financial Impact
Narrow loss of $0.27 per share, $0.03 above consensus
Risk Factors
- Biotech stocks are inherently volatile and sensitive to clinical trial results
- The company remains pre-revenue with significant future funding needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-131792 |
| Document: lxeo-20260330.htm | 0001193125-26-131792 |
| Document: lxeo-ex99_2.htm | 0001193125-26-131792 |
| Document: 0001193125-26-131792-index-headers.html | 0001193125-26-131792 |
| Document: 0001193125-26-131792-index.html | 0001193125-26-131792 |
| Document: 0001193125-26-131792.txt | 0001193125-26-131792 |
| 8-K Data (Synthetic) | 0001193125-26-131792 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G | $2.74 $3.02 | ▲ +10.22% | ▲ +11.37% | $2.70 (−1.46%) |
Sep 22, 2026 4w ago | 8-K | $4.07 $3.42 | ▼ −15.97% | ▼ −14.78% | $2.70 (−33.66%) |
Aug 12, 2026 10w ago | 8-K | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.70 (−44.56%) |
Aug 12, 2026 10w ago | Press Release | $4.87 $5.37 | ▲ +10.27% | ▲ +10.71% | $2.70 (−44.56%) |
Jul 1, 2026 16w ago | Insider Cluster | $4.69 $5.05 | ▲ +7.68% | ▲ +6.75% | $2.70 (−42.43%) |
Jun 17, 2026 18w ago | Press Release | $4.93 $4.70 | ▼ −4.67% | ▼ −3.00% | $2.70 (−45.23%) |
Jun 15, 2026 19w ago | 8-K | $4.65 $5.04 | ▲ +8.39% | ▲ +9.77% | $2.70 (−41.94%) |
Jun 12, 2026 19w ago | Institutional Cluster | $4.37 $4.93 | ▲ +12.81% | ▲ +12.14% | $2.70 (−38.22%) |
May 20, 2026 22w ago | Insider Cluster | $5.23 $5.14 | ▼ −1.72% | ▼ −3.57% | $2.70 (−48.37%) |
May 11, 2026 24w ago | 8-K | $6.12 $4.71 | ▼ −23.04% | ▼ −22.95% | $2.70 (−55.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers